Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ALCMI-011: Study of Plasma Next Generation Sequencing for Assessment, Characterization, Evaluation of Patients With ALK Resistance (SPACEWALK)

NCT03833934 is registered in ClinicalTrials.gov with Addario Lung Cancer Medical Institute as lead sponsor.

NCT NCT03833934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03833934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ALCMI-011: Study of Plasma Next Generation Sequencing for Assessment, Characterization, Evaluation of Patients With ALK Resistance (SPACEWALK)
Lead sponsor
Addario Lung Cancer Medical Institute
Phase
Observational
Overall status
Completed
Start date
January 23, 2019
Completion date
October 31, 2023
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer